Please Wait...

Steve Goldstein

Main profile

Steve Goldstein
Director Study QC, IRT

Mr. Goldstein has over 20 years of regulated systems experience, which includes 13 focused on clinical IRT primarily for a clinical packaging and distribution vendor.  Mr. Goldstein brings a clinical supplies perspective to IRT systems that complements the clinical perspective employed on most IRT teams.  Mr. Goldstein joined BioClinica in 2009, and his current responsibilities include managing the Study QC team. He holds responsibility for study-specific testing, validation, and QC activities of BioClinica's EDC and IRT systems.  Mr. Goldstein received a B.A. in Chemistry from Cornell University and a M.S. in Chemical Engineering from Georgia Tech.

Blogs

With the increasing complexity in protocols and need to increase the cost-effectiveness of studies, your IRT-related decisions play an even greater role in ensuring the most appropriate patient randomization and clinical supply strategies. Gone are the days of being able to use the "tried and true" IRT systems without further consideration of if they meet your protocol requirements.

In the last blog we talked about how technology transfer is gaining ground on the conventional Software as a Service (SaaS) IRT sourcing model. In this blog post, I will explain the advantages of the technology and design behind Trident that make it particularly well-suited for IRT technology transfer. So let's dive right in.

When it comes to Interactive Response Technology (IRT) – systems used to perform subject randomization, drug dispensing and study drug resupply – Software as a Service (SaaS) continues to be the conventional delivery model including here at BioClinica.

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Bioclinica is organized into three business segments so that we can provide expert service and multifaceted technologies. Our Medical Imaging & Biomarkers segment includes an Imaging Core Lab, a Cardiovascular Safety division, and a Molecular Marker Laboratory. Our eHealth segment comprises eClinical Solutions, Randomization & Trial Supply Management, Safety & Regulatory Solutions, and Financial Lifecycle Solutions. Under the Global Clinical Research segment, we offer a network of research sites, patient recruitment, and a Post-Approval Research division.

RT @Xtalks: Outsourcing to #CROs? Top 5 Reasons to Consider Bringing CTMS & Quality Management/RBM Systems in House @bioclinica https://t.c…
bioclinica (7 hours ago)
Webinar tom! Take a fresh look at in-house vs. outsourced #CTMS & #RBM systms via case studies & ROI… https://t.co/cXKG3UgaGp
bioclinica (12 hours ago)
Outsourcing Pharmacovigilance: Pros and Cons and Lessons Learned. Join us at 11 AM EDT today in a live webinar.… https://t.co/1jiraT9cSL
bioclinica (Yesterday)
Still time to join us for tomorrow's webinar: Outsourcing Pharmacovigilance: Pros and Cons and Lessons Learned https://t.co/Ho13oUxdly
bioclinica (2 days ago)
ICYMI: Clean Patient Optics: helping #ClinicalResearch teams meet or beat database lock. News https://t.co/adWwISw4Cu
bioclinica (2 days ago)
Vaccine clinical trials: Boost senior participation following simple advice from Dr. Craig Curtis… https://t.co/rYg9u25vMf
bioclinica (5 days ago)

Latest Blogs: